Nucala patent expiry?

See the DrugPatentWatch profile for Nucala

When is Nucala's Patent Set to Expire?

The patent protection for Nucala (mepolizumab) is expected to expire in the United States in December 2028 [1]. DrugPatentWatch.com tracks patent expiry dates for medications, including Nucala [1].

What Happens When Nucala's Patents Expire?

Following the expiry of Nucala's patents, the market may open to generic or biosimilar versions of the drug. This typically leads to increased competition and potentially lower prices for patients [1].

Can Generic or Biosimilar Versions of Nucala Be Developed Before Patent Expiry?

The development and approval of generic or biosimilar versions of Nucala are subject to patent law and regulatory processes. Companies may challenge existing patents or wait for their expiration to introduce competing products. The exact timeline for potential generic or biosimilar entry can depend on the strength and validity of Nucala's patents, as well as the specific regulatory pathways in different countries [1].

Who Makes Nucala?

Nucala is manufactured by GlaxoSmithKline (GSK) [2].